Sector News

Horizon is world leader in gene-editing with Sage buy

October 1, 2014
Life sciences
The UK’s Horizon Discovery is acquiring Sage Labs of the USA in a deal which it says will create “the world’s leading gene-editing and translational genomics company”.
 
The Cambridge-headquarted group is paying up to $48 million ($16 million in cash and $32 million in new shares) for Sage, described as “a world leader in the generation of advanced in vivo transgenic disease models for use in preclinical research”. It builds upon the $8 million acquisition of CombinatoRx in July and Horizon says it is now the “go-to company for the provision of integrated product, service and research solutions at all stages of translational genomics and personalised medicine research from sequence to treatment”.
 
Sage belonged to Sigma-Aldrich before a buy-out in 2013 and has 50 employees, a direct US and European sales force and 43,000 square feet state-of-the-art facilities. This will enable the scale-up of Horizon’s product and service offerings “through access to new capabilities, capacity and access to new markets”.
 
David Smoller, Sage chief executive who will now become Horizon’s chief business officer, said the new firm “is now the destination for researchers and scientists worldwide to find both in vivo and in vitro solutions to their biological questions”.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

How can we help you?

We're easy to reach